Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Director departure
Inv. presentation
Quarterly results
Consulting agrmnt
Appointed COO
Appointed director
CC transcript
BIOGEN INC. (BIIB) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Quarterly results
07/31/2023 8-K Quarterly results
07/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biogen to Acquire Reata Pharmaceuticals",
"Investor Webcast Presentation, prepared by the Company"
07/25/2023 8-K Quarterly results
06/29/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/03/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
07/20/2022 8-K Quarterly results
06/21/2022 8-K Appointed a new director
05/03/2022 8-K Quarterly results
Docs: "BIOGEN REPORTS FIRST QUARTER 2022 RESULTS"
02/03/2022 8-K Quarterly results
01/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors"
11/19/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
11/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
10/20/2021 8-K Quarterly results
Docs: "BIOGEN REPORTS THIRD QUARTER 2021 RESULTS"
07/22/2021 8-K Quarterly results
Docs: "BIOGEN REPORTS SECOND QUARTER 2021 RESULTS"
06/08/2021 8-K Quarterly results
04/22/2021 8-K Quarterly results
04/09/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
10/21/2020 8-K Asset disposition
Docs: "BIOGEN REPORTS Q3 2020 RESULTS"
09/21/2020 8-K Quarterly results
07/22/2020 8-K Quarterly results
07/21/2020 8-K Quarterly results
06/18/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
06/05/2020 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
04/30/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among the Company, Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters named in Schedule I thereto",
"Second Supplemental Indenture, between the Company and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit B, respectively, thereto",
"Opinion of Foley Hoag LLP as to the validity of the Notes"
04/22/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "BIOGEN REPORTS Q1 2020 REVENUES OF $3.5 BILLION GAAP diluted EPS increased 13%; Non-GAAP diluted EPS increased 31% Biogen has open BLA and has started to submit modules, expects to complete the U.S. filing for aducanumab in third quarter Biogen initiated re-dosing study for aducanumab and higher dose study for SPINRAZA Biogen entered collaboration with Sangamo Therapeutics for gene regulation therapies for neurological disease"
04/20/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SECURITIES AND EXCHANGE COMMISSION"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy